Table 9.
Summary of Patients with Increase from Baseline in C-SSRS Scores (Safety Population)
| |
Lead-in study (8-weeks) |
Combined double-blind treatment (24–32 weeks)a |
||
|---|---|---|---|---|
| Placebo n (%) n=128 | Escitalopram n (%) n=131 | Placebo n (%) n=128 | Escitalopram n (%) n=131 | |
| Any suicidal behavior and/or ideation | 13 (10.2) | 12 (9.2) | 14 (10.9) | 19 (14.5) |
| Suicidal behavior | 3 (2.3) | 2 (1.5) | 3 (2.3) | 4 (3.1) |
| Suicidal Ideation | 12 (9.4) | 12 (9.2) | 13 (10.2) | 19 (14.5) |
a
For safety analyses, the combined double-blind treatment period consisted of the 8-week lead-in period and the 16–24-week double-blind extension.